Carbiotix AB
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CRBX.ST research report →
Companywww.carbiotix.com
Carbiotix AB is a pre-clinical stage therapeutics company. It engages in the provision of products and medicines that produce good bacteria from intestine to counter metabolic and chronic diseases. The company was founded in 2014 and is headquartered in Lund, Sweden.
- CEO
- Erik Deaner
- IPO
- 2019
- Employees
- 8
- HQ
- Lund, SE
Price Chart
Valuation
- Market Cap
- $32.74M
- P/E
- -2.25
- P/S
- 36.97
- P/B
- 1.41
- EV/EBITDA
- -2.25
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 296.12%
- Op Margin
- -1632.31%
- Net Margin
- -1632.30%
- ROE
- -63.33%
- ROIC
- -62.62%
Growth & Income
- Revenue
- $978.91K · -33.20%
- Net Income
- $-16,131,191 · -19.67%
- EPS
- $-4.29 · 84.43%
- Op Income
- $-15,993,953
- FCF YoY
- -54.58%
Performance & Tape
- 52W High
- $14.75
- 52W Low
- $3.70
- 50D MA
- $6.38
- 200D MA
- $8.87
- Beta
- 0.13
- Avg Volume
- 7.35K
Get TickerSpark's AI analysis on CRBX.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CRBX.ST Coverage
We haven't published any research on CRBX.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CRBX.ST Report →